Synlogic Provides Corporate Update and Outlook for 2024

- Data review from pivotal Synpheny-3 study in PKU expected in H1 2024, with potential to expand study population to patients aged 12-17 years of age - - Top-line, Phase 3 data in PKU expected in H1 2025 - CAMBRIDGE, Mass. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc.